Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
Christie Mitri, Zhengzhong Xu, Pauline Bardin, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2021) Vol. 271, Iss. 2, pp. 249-258
Open Access | Times Cited: 115
Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives
Soraia C. Abreu, Miquéias Lopes‐Pacheco, Daniel J. Weiss, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 61
The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
Caitlyn Harvey, Sinéad Weldon, J.S. Elborn, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3513-3513
Open Access | Times Cited: 41
Cystic Fibrosis and Oxidative Stress: The Role of CFTR
Evelina Moliteo, Monica Sciacca, Antonino Palmeri, et al.
Molecules (2022) Vol. 27, Iss. 16, pp. 5324-5324
Open Access | Times Cited: 32
First Wave of COVID-19 in French Patients with Cystic Fibrosis
Harriet Corvol, Sandra de Miranda, Lydie Lemonnier, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 11, pp. 3624-3624
Open Access | Times Cited: 41
Small-molecule drugs for cystic fibrosis: Where are we now?
Onofrio Laselva, Lorenzo Guerra, Stefano Castellani, et al.
Pulmonary Pharmacology & Therapeutics (2021) Vol. 72, pp. 102098-102098
Closed Access | Times Cited: 37
Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection
Olivier Guillaume, Cosmin Butnarasu, Sonja Visentin, et al.
Biofilm (2022) Vol. 4, pp. 100089-100089
Open Access | Times Cited: 24
Innate Immunity in Cystic Fibrosis: Varied Effects of CFTR Modulator Therapy on Cell-to-Cell Communication
J. Hynes, Clifford C. Taggart, Rabindra Tirouvanziam, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2636-2636
Open Access
Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections
Dana Holger, Razieh Kebriaei, Taylor Morrisette, et al.
Antibiotics (2021) Vol. 10, Iss. 5, pp. 556-556
Open Access | Times Cited: 24
Impact of mucus and biofilm on antimicrobial photodynamic therapy: Evaluation using Ruthenium(II) complexes
Raphaëlle Youf, Rosy Ghanem, Adeel Nasir, et al.
Biofilm (2023) Vol. 5, pp. 100113-100113
Open Access | Times Cited: 9
Akt-driven TGF-β and DKK1 Secretion Impairs F508del Cystic Fibrosis Airway Epithelium Polarity
Tahir Idris, Michaël Bachmann, Matthew Bacchetta, et al.
American Journal of Respiratory Cell and Molecular Biology (2024) Vol. 71, Iss. 1, pp. 81-94
Closed Access | Times Cited: 3
Lung Disease Management by Iloprost-Loaded Nanoparticles to Address Hyperinflammation Associated with Cystic Fibrosis
Emanuela Fabiola Craparo, Marta Cabibbo, Cinzia Scialabba, et al.
ACS Applied Nano Materials (2024) Vol. 7, Iss. 12, pp. 14077-14089
Closed Access | Times Cited: 3
Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches
Alessandra Ghigo, Giulia Prono, Elisa Riccardi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1952-1952
Open Access | Times Cited: 22
Pulmonary biofilm-based chronic infections and inhaled treatment strategies
Li Ding, Jieliang Wang, Shihao Cai, et al.
International Journal of Pharmaceutics (2021) Vol. 604, pp. 120768-120768
Closed Access | Times Cited: 22
Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies
Cosmin Butnarasu, Giulia Caron, Daniela Pacheco, et al.
Molecular Pharmaceutics (2021) Vol. 19, Iss. 2, pp. 520-531
Open Access | Times Cited: 22
Xylitol as a Hydrophilization Moiety for a Biocatalytically Synthesized Ibuprofen Prodrug
Federico Zappaterra, Chiara Tupini, Daniela Summa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2026-2026
Open Access | Times Cited: 14
Anti‐Inflammatory Potential of Chalcone Related Compounds: An Updated Review
Anup Yadav, Vikas Sharma, Gurdeep Singh
ChemistrySelect (2024) Vol. 9, Iss. 26
Closed Access | Times Cited: 2
Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells
Onofrio Laselva, Caterina Allegretta, Sante Di Gioia, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 2132-2132
Open Access | Times Cited: 13
Lactobacillus brevis BGZLS10-17 and Lb. plantarum BGPKM22 Exhibit Anti-Inflammatory Effect by Attenuation of NF-κB and MAPK Signaling in Human Bronchial Epithelial Cells
Marija Stanković, Katarina Veljović, Nikola Popović, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5547-5547
Open Access | Times Cited: 9
Oxidative stress and impaired insulin secretion in cystic fibrosis pig pancreas
Yunxia O’Malley, Mitchell C. Coleman, Xingshen Sun, et al.
Advances in Redox Research (2022) Vol. 5, pp. 100040-100040
Open Access | Times Cited: 8
Adjunctive nano‐curcumin therapy improves inflammatory and clinical indices in children with cystic fibrosis: A randomized clinical trial
Saeedeh Talebi, Andrew S. Day, Mahammad Safarian, et al.
Food Science & Nutrition (2023) Vol. 11, Iss. 6, pp. 3348-3357
Open Access | Times Cited: 4
Assessing the Potential of N-Butyl-l-deoxynojirimycin (l-NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent
Anna Esposito, Alice S. Rossi, Maria Rosaria Stabile, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 6, pp. 1807-1822
Open Access | Times Cited: 1
Lung-AdaptedStaphylococcus aureusIsolates With Dysfunctional Agr System Trigger a Proinflammatory Response
Elodie Ramond, Agathe Lepissier, Xiongqi Ding, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 7, pp. 1276-1285
Closed Access | Times Cited: 7
SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
Carmelo Biondo, Angelina Midiri, Elisabetta Gerace, et al.
Life (2022) Vol. 12, Iss. 12, pp. 2087-2087
Open Access | Times Cited: 7
Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis
Carsten Schwarz, Claudio Procaccianti, Laura Costa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9597-9597
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top